Business UpdateJun 24, 2026, 08:02 AM
Calidi Biotherapeutics Presents RedTail Platform Data; IND for CLD-401 by EOY
AI Summary
Calidi Biotherapeutics presented new data on its RedTail platform at the T-cell Engager Therapeutic Summit, demonstrating its approach to simultaneously activate T-cells and induce T-cell engager expression in the tumor microenvironment. The company highlighted the platform's potential to overcome historical limitations of T-cell engagers in solid tumors. Calidi expects to file an Investigational New Drug (IND) application for its lead candidate, CLD-401, by the end of 2026. Additionally, Calidi is developing CLD-501 targeting TROP2 and exploring other targets, while actively seeking strategic partnerships.
Key Highlights
- Calidi presented data on its RedTail platform at the T-cell Engager Therapeutic Summit.
- Data showed RedTail's ability to activate T-cells and express T-cell engagers in the tumor microenvironment.
- Company expects to file an IND for lead candidate CLD-401 by the end of 2026.
- RedTail platform is designed to overcome limitations of T-cell engagers in solid tumors.
- Developing CLD-501 targeting TROP2, and pursuing EGFR, EpCAM, and Nectin-4 targets.
- Actively pursuing strategic partnerships to accelerate clinical development of RedTail platform.
Price Impact
More from CLDI